CD14 and cancer: Consistent with previous studies, we observed that the abundance of CD14+HLA-DR–/low cells was correlated with the cancer stage where a significant increase was seen in the percentage of circulating CD14+HLA-DR–/low cells among advanced stage (stage III/IV) OC patients (21.5% ± 8.3%) as compared with early stage (stage I/II) OC patients (12.9% ± 4.3%) (Figure 1B).